

Pharmaceutical Policies Updates Effective December 1, 2021

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2021 and will be available for viewing on or before November 1, 2021. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Chelating Select Agents	Updated
Gaucher Disease Type 1 Treatment	Updated
Hereditary Angioedema	Updated
Colony Stimulating Factors	Updated
Enteral Therapy – New York	Updated
Enteral Therapy - Vermont	Updated
Lidocaine (Topical) Products	Updated
Diclofenac (Topical) Products	Updated
Adakveo	Reviewed
Erythropoiesis Stimulating Agents (ESAs)	Reviewed
Hemophilia Factor	Updated
Patient Medication Safety	Updated
Dojolvi	New
Cystic Fibrosis (Select Agents for Inhalation) (effective October 1, 2021)	Updated
Preventive Services – Medications (effective September 1, 2021)	Updated
Tepezza (teprotumumab-trbw)	New

To receive future FastFax messages by email, go to mvphealthcare.com/provideremail

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

